Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis
Abstract The aim was to analyze the relationship between peficitinib exposure and efficacy response according to American College of Rheumatology (ACR) 20 criteria and 28‐joint disease activity score based on C‐reactive protein (DAS28‐CRP) in rheumatoid arthritis (RA) patients, and to identify relev...
Main Authors: | Junko Toyoshima, Atsunori Kaibara, Mai Shibata, Yuichiro Kaneko, Hiroyuki Izutsu, Tetsuya Nishimura |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | Pharmacology Research & Perspectives |
Subjects: | |
Online Access: | https://doi.org/10.1002/prp2.744 |
Similar Items
-
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib
by: Magnus Diller, et al.
Published: (2019-03-01) -
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
by: Tsutomu Takeuchi, et al.
Published: (2020-03-01) -
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis
by: Yoshiya Tanaka, et al.
Published: (2021-08-01) -
Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
by: Yuzo Ikari, et al.
Published: (2019-06-01) -
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
by: Mark C. Genovese, et al.
Published: (2019-08-01)